Cohort Study | Stopping immunotherapy in patients that are progression-free at 2 years seems feasible in advanced NSCLC

Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

News Release: Real-World Data Suggests Stopping Immunotherapy after Two Years is Reasonable in Patients with Advanced Lung Cancer – Penn Medicine

Commentary on Twitter

Study of patients with #NSCLC showed no survival difference between 2-yr fixed duration vs indefinite #immunotherapy, suggesting that IO can be d/c at 2 yrs. @PennCancer @flatironhealth @lovasunMD @Ron_cology @CharuAggarwalMD #ASCO23 https://t.co/EWyneghc8a pic.twitter.com/HkyIwwtJiM

— JAMA Oncology (@JAMAOnc) June 4, 2023